Despite 25 years of clinical trials, there has been only modest progress in improving treatment of rifampin-susceptible TB.
A perspective, published in PLOS Medicine, proposes a shift in the focus of the clinical trials to improving the safety and acceptability of treatment, rather than treatment-shortening. Because adverse events increase the risk of treatment failure and recurrence, a focus on safety and acceptability should result in an improvement in both the patient’s experience of treatment and traditional TB treatment outcomes.
For more TB updates, check out the latest edition of the TB Online Weekly Newsletter (#26, 28 August 2024).
Related HIV and Co-Infections News
-
The Lancet Global Health: Untangling the complex relationship between HIV-exposure and TB in children: A narrative review
-
Research Centre Borstel: Long-term cure rates for multidrug-resistant TB much better than expected
-
Liverpool School of Tropical Medicine: New pooled testing toolkit to help expand TB diagnosis to ‘missed millions’
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.